251 related articles for article (PubMed ID: 28606095)
1. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
Suzuki S; Oura T; Takeuchi M; Boye KS
Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Yu M; Brunt KV; Milicevic Z; Varnado O; Boye KS
Clin Ther; 2017 Nov; 39(11):2284-2295. PubMed ID: 29110972
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
Araki E; Inagaki N; Tanizawa Y; Oura T; Takeuchi M; Imaoka T
Diabetes Obes Metab; 2015 Oct; 17(10):994-1002. PubMed ID: 26179754
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
[TBL] [Abstract][Full Text] [Related]
7. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
Miyagawa J; Odawara M; Takamura T; Iwamoto N; Takita Y; Imaoka T
Diabetes Obes Metab; 2015 Oct; 17(10):974-83. PubMed ID: 26179187
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M; Van Brunt K; Varnado OJ; Boye KS
Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
[TBL] [Abstract][Full Text] [Related]
11. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
[TBL] [Abstract][Full Text] [Related]
12. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
[TBL] [Abstract][Full Text] [Related]
13. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.
Lasalvia P; Baquero L; Otálora-Esteban M; Castañeda-Cardona C; Rosselli D
Value Health Reg Issues; 2017 Dec; 14():35-40. PubMed ID: 29254540
[TBL] [Abstract][Full Text] [Related]
15. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
17. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
[TBL] [Abstract][Full Text] [Related]
19. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
[TBL] [Abstract][Full Text] [Related]
20. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
Takase T; Nakamura A; Yamamoto C; Nomoto H; Miya A; Dannoura M; Cho KY; Kurihara Y; Manda N; Aoki S; Atsumi T; Miyoshi H
J Diabetes Investig; 2019 May; 10(3):699-705. PubMed ID: 30076787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]